Exciting news for investors! The Emcure Pharmaceuticals IPO subscription status is now open for subscriptions starting July 3.
At an upper price range of ₹1,008 per equity share, Emcure Pharmaceuticals Ltd successfully raised ₹582 crore from 48 anchor investors on July 2.
Backed by Bain Capital, the Emcure Pharmaceuticals IPO offers a price band of ₹960 to ₹1,008 per share and will close on July 5.
Emcure Pharmaceuticals, based in Pune, specializes in the development, production, and global marketing of a wide range of pharmaceutical products in various therapeutic areas.
A total of 108,900 equity shares from the employee portion have been allocated for the IPO. Qualified institutional investors (QIBs) will receive 50% of the issue size, retail investors 35%, and non-institutional investors the remaining 15%.
Investors can bid for a minimum of 14 shares and in multiples of 14 thereafter.
Exciting potential ahead! Check out how Shark Tank’s Namita Thapar stands to earn ₹127 crore from OFS in the Emcure Pharmaceuticals IPO.
Emcure Pharmaceuticals IPO Review
Emcure Pharmaceuticals is a significant player in the pharmaceutical industry, boasting a strong R&D setup, diverse product range, and brand-building expertise, both locally and globally.
While Emcure has shown consistent growth in its top line, recent depreciation and interest costs have marginally impacted profitability.
However, potential concerns exist, such as disruptions in the raw material supply chain due to heavy regulation in the pharmaceutical sector, and dependence on external partners for product distribution.
The 36.6x P/E value is deemed suitable by the brokerage, considering Emcure’s capabilities, growth prospects, and potential debt reduction post-IPO.
Long-term investors are encouraged to consider applying for this IPO.
Anand Rathi Research
Anand Rathi Research believes Emcure Pharmaceuticals is fairly valued at a P/E of 36x post-equity share issuance based on FY24 earnings.
With favorable market trends and potential for business expansion, the brokerage sees room for growth and recommends a “SUBSCRIBE – long term” rating for the IPO.
Curious about the Emcure Pharma IPO’s GMP signals before opening for subscription? Find out more here.
Emcure Pharmaceuticals IPO details
The IPO includes a fresh offering of ₹800 crore and an offer by existing promoters and shareholders to sell ₹1,151 crore.
At the peak of the price band, the issue size amounts to ₹1,952 crore.
Promoters Satish Ramanlal Mehta, Sunil Rajanikant Mehta, Namita Vikas Thapar, and Samit Satish Mehta are among the selling shareholders in the OFS.
Additionally, Pushpa Rajnikant Mehta, Bhavana Satish Mehta, Kamini Sunil Mehta, Arunkumar Purshotamlal Khanna, Berjis Minoo Desai, and Sonali Sanjay Mehta, along with BC Investments IV, will offload shares in the OFS.
Key players handling the Emcure Pharma IPO include Axis Capital Limited, J.P. Morgan India Private Limited, Jefferies India Private Limited, and Kotak Mahindra Capital Company Limited as book running lead managers, with Link Intime India Private Ltd serving as the registrar.
Get the latest update on the Emcure Pharmaceuticals IPO’s price band set at ₹960-1,008 apiece, with Namita Thapar planning a partial stake offload.
Emcure Pharmaceuticals IPO GMP today
Today’s Emcure Pharma IPO GMP stands at +299, indicating a premium of ₹299 in the grey market.
With this premium and the upper end of the IPO price band, the expected listing price for Emcure Pharma IPO is ₹1,307 apiece, reflecting a 29.66% increase over the IPO price of ₹1,008.
‘Grey market premium’ highlights investor willingness to pay more than the issue price, showcasing strong demand.
Don’t miss out on potential opportunities! Stay informed about the latest developments in the Emcure Pharmaceuticals IPO.
Disclaimer: Please note that the information provided is based on individual analysis and brokerage recommendations.
Seek advice from accredited financial experts before making any investment decisions.
